FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
1. FibroBiologics advances Bone Marrow Organoid platform for cancer treatments. 2. Pre-IND trials show promising results in reducing tumor size. 3. Organoids allow efficient gene editing for targeted interventions. 4. Potential applications extend to immune function restoration and advanced therapies. 5. Technology marks a critical step towards clinical translation.